Angeliki Panagiotou NEPHROLOGIST Consultant, Nephrology Centre (Centre for diagnosis, treatment & research on kidney diseases)

University of Patras, School of Medicine, Greece

TITLE: Antiplatelet effects of prasugrel versus double clopidogrel in patients on    hemodialysis and with high on-treatment platelet reactivity

1. Hellenic Society of Nephrology
2. European Renal Association-European Dialysis Transplant Association
3. European Association for the Study of Diabetes (EASD)
4. European Diabetic Nephropathy Study Group (EDNSG)
5. Member of General Medical Council (GMC)

• 6/2019: Consultant, Centre for Diagnosis, Treatment & Research on Kidney Diseases
• 2018-2019: Clinical fellow, ERA-EDTA Young Fellowship Programme, in collaboration with the Hellenic Society of Nephrology and the Stavros Niarchos Foundation, King’s College London, Guy’s and St Thomas’ Foundation NHS Trust, Department of Diabetes & Endocrine, London, United Kingdom
• 2014-2018: Specialty Registrar in Nephrology, Centre for Nephrology “G. Papadakis”, General Hospital of Nikaia-Pireaus
• 2012-2014: Resident Doctor in Internal Medicine, 2nd Department of Internal Medicine, General Hospital of Nikaia- Pireaus
• 2010-2011: Community Doctor, General Hospital of Mesolongi “Chatzikosta”- Health Center of Ano Hora, Nafpaktos, Greece
• 2009-2010: Research Fellow, Cardiology Department, University Hospital of Patras

Clinical Experience:

My clinical experience lies in all the fields of Nephrology (Clinical Nephrology, Hemodialysis, Peritoneal Dialysis) and this is because the Nephrology Centers I was trained and educated are the most experienced in their countries. My main interest is Diabetic Nephropathy and cardiovascular complications of Diabetes Mellitus as I was trained and subspecialized in Metabolic Unit of King’s College London.

Educational Experience

• Fabry patients in Greece 5th Fabry Expert Meeting, Athens, 2017
• Fabry disease: From laboratory to everyday clinical practice Scientific meeting for Lysosomal Diseases, Athens, 2016
• IgA Nephropathy: Case report Centre for Nephrologyn 19th Panhellenic Congress of Nephrology, Kalamatas, 2016

Clinical Interest:

• Clinical Nephrology and mainly Diabetic Nephropathy
• Renal Replacement Therapy (Haemodialysis)
• Lysosomal diseases (Fabry disease)

Research Interest:

The clinical and epidemiological research in Diabetic Nephropathy emphasizing in newer therapies of Diabetes Mellitus and risk factors for renal and cardiovascular complications of diabetes with the development of prognostic models of progression.

Clinical Fellowship. ERA-EDTA Young Clinical Fellowships for Greek Nephrologists Programme 2018

10/2018 – 6/2019: Guy’s and St Thomas’ NHS Foundation Trust, Diabetes & Endocrine Department, London, United Kingdom

1. IgA nephropathy in Greece: Data from the registry of the Hellenic Society of Nephrology  Stangou, M. Papasotiriou, D. Xydakis, T. Oikonomaki, S. Marinaki, S. Zerbala, C. Stylianou, P. Kalliakmani, A. Aimilios, A. Papadaki, O. Balafa, S. Golfinopoulos, G. Visvardis, G. Moustakas, E. Papachristou, T. Kouloukourgiotou, E. Kapsia, A. Panagiotou, C. Koulousios, C. Kavlakoudis, M. Georgopoulou, S. Panagoutsos, D. Vlahakos, T. Apostolou, I. Stefanidis, C. Siamopoulos, I. Tzanakis, A. Papadogiannakis, E. Daphnis, C. Iatrou, I. Boletis, A. Papagianni, D. Goumenos Clin Kidney J. 2018 Feb; 11(1):38-45. doi: 10.1093/ckj/sfx076
2. Oral Antiplatelet Agents in Dialysis Patients: Friends or Foes? Fourtounas C, Panagiotou A. Gen Med (Los Angel) 2013, 1:3, http://dx.doi.org/10.4172/2327-5146.1000109
3. Prevalence of inadequate platelet inhibition by clopidogrel in patients receiving hemodialysis. Alexopoulos D, Xanthopoulou I, Panagiotou A, Komninakis D, Germanos N, Goudas P, Koutroulia E, Fourtounas C.  Am J Kidney Dis. 2012 Mar;59(3):469-71. doi: 10.1053/j.ajkd.2011.10.045. 
4. Oral antiplatelet agents and chronic kidney disease Alexopoulos D, Panagiotou A. Hellenic J Cardiol. 2011 Nov-Dec;52(6):509-15.
5. Long-term clinical outcome after percutaneous coronary intervention in grafts vs native vessels in patients with previous coronary artery bypass grafting Xanthopoulou I, Davlouros P, Tsigkas G, Panagiotou A, Hahalis G, Alexopoulos D.  Can J Cardiol. 2011 Nov-Dec;27(6):716-24. doi: 10.1016/j.cjca.2011.08.115. 
6. Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. Alexopoulos D, Panagiotou A, Xanthopoulou I, Komninakis D, Kassimis G, Davlouros P, Fourtounas C, Goumenos D.  J Thromb Haemost. 2011 Dec;9(12):2379-85. doi: 10.1111/j.1538-7836.2011.04531.x.
7. Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. Alexopoulos D, Xanthopoulou I, Davlouros P, Plakomyti TE, Panagiotou A, Mavronasiou E, Hahalis G.  Am Heart J. 2011 Oct;162(4):733-9. doi: 10.1016/j.ahj.2011.07.026. 
8. Prevalence of contraindications and conditions for precaution for prasugrel administration in a real world acute coronary syndrome population. Alexopoulos D, Xanthopoulou I, Mylona P, Perperis A, Panagiotou A, Dimitropoulos G, Tsigkas G, Hahalis G, Davlouros P. J Thromb Thrombolysis. 2011 Oct;32(3):328-33. doi: 10.1007/s11239-011-0610-